MESA LABORATORIES INC /CO/

For the period ended Dec 31, 2025. Filed Feb 3, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Dec 31, 2025 · Filed Feb 3, 2026

MLAB$127.82-0.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

M****esa Laboratories, Inc.**

Condensed Consolidated Balance Sheets

(in thousands, except share amounts)

	December 31,	March 31,
	2025	2025
ASSETS
Current assets:
Cash and cash equivalents	$28,975	$27,321
Accounts receivable, less allowance for credit losses of $2,523 and $1,186, respectively	40,233	41,970
Inventories	26,559	25,365
Prepaid expenses and other current assets	9,865	8,029
Total current assets	105,632	102,685
Noncurrent assets:
Property, plant and equipment, net of accumulated depreciation of $29,901 and $26,421, respectively	31,599	32,333
Deferred tax asset	1,474	1,371
Other assets	17,195	18,324
Customer relationships, net	67,898	72,880
Other intangibles, net	21,748	23,995
Goodwill	189,303	181,760
Total assets	$434,849	$433,348
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$5,253	$5,747
Accrued payroll and benefits	13,879	17,858
Unearned revenues	14,558	14,710
Other accrued expenses	15,549	24,601
Term loan, current portion	5,156	3,750
Convertible notes, net of debt issuance costs	-	97,297
Total current liabilities	54,395	163,963
Noncurrent liabilities:
Deferred tax liability	21,831	20,181
Other noncurrent liabilities	10,961	12,472
Term loan, noncurrent portion, net of debt issuance costs	62,721	66,902
Revolving line of credit	98,250	10,000
Total liabilities	248,158	273,518
Stockholders’ equity:
Common stock, no par value; authorized 25,000,000 shares; issued and outstanding, 5,524,813 and 5,455,421 shares, respectively	368,555	358,541
(Accumulated deficit)	(180,727)	(188,936)
Accumulated other comprehensive (loss)	(1,137)	(9,775)
Total stockholders’ equity	186,691	159,830
Total liabilities and stockholders’ equity	$434,849	$433,348

See accompanying notes to Condensed Consolidated Financial Statements.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.